^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Metastatic Pancreatic Cancer: ASCO Guideline Update

Published date:
08/05/2020
Excerpt:
Recommendations…Treatment Options After First-Line Therapy…In patients with tumors harboring NTRK fusions, treatment with larotrectinib or entrectinib is recommended…
DOI:
10.1200/JCO.20.01364 Journal of Clinical Oncology
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Sarcoma)
New
Title:

New sarcoma drug approved for use in England

Excerpt:
We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset

Published date:
07/04/2021
Excerpt:
As of July 20, 2020, 18 patients with metastatic TRK fusion-positive GI cancer were enrolled...The other tumor types were cholangiocarcinoma (n=3), pancreatic (n=2), appendiceal (n=1), esophageal (n=1), and hepatocellular carcinoma (n=1)….In patients with TRK fusion-positive GI cancer, larotrectinib demonstrated rapid responses with high survival rates and a favorable safety profile.
DOI:
10.1016/j.annonc.2021.05.053
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Larotrectinib efficacy and safety in adult TRK fusion cancer patients.

Excerpt:
TRK fusions involved NTRK1 (40%), NTRK2 (2%), and NTRK3 (57%)….Larotrectinib demonstrated robust tumor-agnostic efficacy and a favorable safety profile in adult pts with TRK fusion cancer.
DOI:
10.1200/JCO.2019.37.15_suppl.3122